Efficacy of JAK1/2 inhibition in murine immune bone marrow failure
Blood · 2023
DOI: 10.1182/blood.2022015898 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Emma M Groarke und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. Hauptthemen laut MEDLINE: Pancytopenia, Anemia, Aplastic, Bone Marrow Diseases. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Immune aplastic anemia (AA) is a severe blood disease characterized by T-lymphocyte− mediated stem cell destruction. Hematopoietic stem cell transplantation and immunosuppression are effective, but they entail costs and risks, and are not always successful. The Janus kinase (JAK) 1/2 inhibitor ruxolitinib (RUX) suppresses cytotoxic T-cell activation and inhibits cytokine production in models of graft-versus-host disease. We tested RUX in murine immune AA for potential therapeutic benefit. After infusion of lymph node (LN) cells mismatched at the major histocompatibility complex [C67BL/6 (B6)⇒CByB6F1], RUX, administered as a food additive (Rux-chow), attenuated bone marrow hypoplasia, ameliorated peripheral blood pancytopenia, preserved hematopoietic progenitors, and prevented mortality, when used either prophylactically or therapeutically. RUX suppressed the infiltration, proliferation, and activation of effector T cells in the bone marrow and mitigated Fas-mediated apoptotic destruction of target hematopoietic cells. Similar effects were obtained when Rux-chow was fed to C.B10 mice in a minor histocompatibility antigen mismatched (B6⇒C.B10) AA model. RUX only modestly suppressed lymphoid and erythroid hematopoiesis in normal and irradiated CByB6F1 mice. Our data support clinical trials of JAK/STAT inhibitors in human AA and other immune bone marrow failure syndromes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
ORCID-Profile: Emma M Groarke, Xingmin Feng, Nidhi Aggarwal, Zhijie Wu, Bhavisha A Patel
Zitieren
APA
Groarke, E. M., Feng, X., Aggarwal, N., Manley, A. L., Wu, Z., Gao, S., Patel, B. A., Chen, J., & Young, N. S. (2023). Efficacy of JAK1/2 inhibition in murine immune bone marrow failure. Blood. https://doi.org/10.1182/blood.2022015898
Vancouver
Groarke EM, Feng X, Aggarwal N, Manley AL, Wu Z, Gao S, et al. Efficacy of JAK1/2 inhibition in murine immune bone marrow failure. Blood. 2023. doi:10.1182/blood.2022015898
BibTeX
@article{Groarke2023,
author = {Groarke, Emma M and Feng, Xingmin and Aggarwal, Nidhi and Manley, Ash Lee and Wu, Zhijie and Gao, Shouguo and Patel, Bhavisha A and Chen, Jichun and Young, Neal S},
title = {Efficacy of JAK1/2 inhibition in murine immune bone marrow failure},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022015898}
}
EUVIMED